| Literature DB >> 32767113 |
Alex R Jenkins1, Neil S Holden2, Arwel W Jones3.
Abstract
OBJECTIVE: Pulmonary rehabilitation is a cornerstone treatment in the management of chronic obstructive pulmonary disease (COPD). Acute bouts of exercise can lead to short bursts of inflammation in healthy individuals. However, it is unclear how COPD patients respond to acute bouts of exercise. This study assessed inflammatory responses to exercise in COPD patients at the start (phase 1) and end (phase 2) of pulmonary rehabilitation.Entities:
Keywords: Exercise immunology; Lung disease; Systemic inflammation
Mesh:
Substances:
Year: 2020 PMID: 32767113 PMCID: PMC7502052 DOI: 10.1007/s00421-020-04452-z
Source DB: PubMed Journal: Eur J Appl Physiol ISSN: 1439-6319 Impact factor: 3.078
Fig. 1Study procedures
Patient characteristics (phases 1 and 2)
| Variable | COPD, phase 1 ( | COPD, phase 2 ( |
|---|---|---|
| Age (years)a | 69 ± 7 | 69 ± 7 |
| % Malesb | 58% | 56% |
| Body mass (kg)a | 77 ± 17 | 74 ± 15 |
| GOLD grade, | ||
| A | 1 (2) | 1 (4) |
| B | 13 (33) | 10 (37) |
| C | 0 (0) | 0 (0) |
| D | 26 (65) | 16 (59) |
| FEV1% predicteda | 51 ± 17 | 50 ± 16 |
| Charlson Comorbidity Indexa | 3.9 ± 1.1 | 4.0 ± 1.2 |
| Current smokersb | 23% | 19% |
| Oxygen usersb | 15% | 11% |
| Hospitalisations (past 12 months)a | 0.5 ± 0.7 | 0.4 ± 0.7 |
| Exacerbations (past 12 months)a | 2.2 ± 1.6 | 2.1 ± 1.6 |
| Daily beclomethasone equivalent (µg)a | 860 ± 540 | 889 ± 621 |
| mMRC, | ||
| 0 | 1 (2) | 1 (4) |
| 1 | 0 (0) | 0 (0) |
| 2 | 6 (15) | 4 (15) |
| 3 | 12 (30) | 9 (33) |
| 4 | 21 (53) | 13 (48) |
| Average exercise duration (min)a | 26 ± 4 | 40 ± 4 |
aData presented as mean ± SD
bData presented as a % of total population
cData presented as total number
Fig. 2Fibrinogen (a), CRP (b), total leukocyte (c), neutrophil (d), lymphocyte (e), and eosinophil (f) responses to an acute bout of exercise at the beginning of pulmonary rehabilitation (phase 1)
Responses of neutrophil activation markers and maturity phenotypes to acute exercise at the beginning of pulmonary rehabilitation
| Neutrophil marker | 2nd pre ( | 2nd post ( | |
|---|---|---|---|
| CD11b (MFI) | 5508 ± 791 | 5495 ± 748 | 0.470 |
| CD62L (MFI) | 26,852 ± 6185 | 26,534 ± 5523 | 0.352 |
| CD66b (MFI) | 9447 ± 2956 | 9604 ± 2930 | 0.334 |
| CD16bhigh/CD62Lhigh (%) | 92.6 ± 3.0 | 92.6 ± 2.2 | 0.414 |
| CD16bhigh/CD62Llow (%) | 5.5 ± 3.2 | 4.9 ± 2.5 | 0.073 |
| CD16blow/CD62Llow (%) | 0.1 ± 0.1 | 0.2 ± 0.2 | 0.210 |
| CD16blow/CD62Lhigh (%) | 1.7 ± 0.8 | 2.3 ± 1.1 | < 0.001 |
Data presented as mean ± SD. MFI median fluorescent intensity. Thirteen COPD patients were excluded from these analyses due to a lack of expression of CD16b meaning that neutrophils could not be confidently isolated for analysis. A further seven COPD patients did not provide blood samples for analysis of neutrophil activation markers
Comparisons of mean differences in systemic inflammatory responses to acute bouts of exercise at the beginning and end of pulmonary rehabilitation
| Variable | 2nd class | 16th class | Difference in classes for change post-exercise | |||
|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | |||
| Fibrinogen (mg/dL), | 694 ± 189 | 654 ± 181 | 588 ± 197 | 632 ± 191 | 84 (− 14, 182) | 0.045* |
| CRP (mg/L), | 13.3 ± 15.0 | 14.2 ± 16.0 | 14.2 ± 14.4 | 15.0 ± 16.5 | − 0.1 (− 2.8, 2.7) | 0.483 |
| Total Leukocytes (109 L−1), | 7.12 ± 1.81 | 7.48 ± 1.60 | 6.70 ± 1.24 | 7.39 ± 1.51 | 0.33 (− 0.33, 0.98) | 0.159 |
| Neutrophils (109 L−1), | 4.22 ± 1.24 | 4.61 ± 1.13 | 3.90 ± 1.02 | 4.43 ± 1.19 | 0.14 (− 0.33, 0.60) | 0.279 |
| Eosinophils (109 L−1), | 0.21 ± 0.11 | 0.20 ± 0.10 | 0.20 ± 0.11 | 0.20 ± 0.11 | − 0.01 (− 0.03, 0.01) | 0.155 |
| Lymphocytes (109 L−1), | 1.93 ± 0.61 | 1.91 ± 0.56 | 1.90 ± 0.54 | 1.97 ± 0.54 | 0.09 (− 0.06, 0.24) | 0.119 |
Data expressed as mean ± SD or mean difference (95% CI)
aPlasma samples unable to be obtained from two COPD patients for measurement of fibrinogen
*Significant difference between bouts in fibrinogen response to exercise (p < 0.05)
Comparison of mean differences for neutrophil activation markers and maturity phenotypes in response to acute exercise at the beginning and end of pulmonary rehabilitation
| Neutrophil marker | 2nd class | 16th class | Difference in classes for change post-exercise | |||
|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | |||
| CD11b (MFI) | 5390 ± 756 | 5469 ± 822 | 5744 ± 855 | 5673 ± 845 | − 150 (− 584, 284) | 0.236 |
| CD62L (MFI) | 25,627 ± 5320 | 25,711 ± 5285 | 28,293 ± 5427 | 27,341 ± 6770 | − 1036 (− 3526, 1453) | 0.195 |
| CD66b (MFI) | 9179 ± 3079 | 9334 ± 3033 | 10,364 ± 1496 | 10,501 ± 1577 | − 18 (− 815, 780) | 0.481 |
| CD16bhigh/CD62Lhigh (%) | 92.49 ± 3.41 | 92.34 ± 2.37 | 92.45 ± 2.34 | 91.51 ± 1.91 | − 0.79 (− 1.98, 0.39) | 0.086 |
| CD16bhigh/CD62Llow (%) | 5.80 ± 3.55 | 5.34 ± 2.61 | 5.43 ± 2.42 | 5.84 ± 2.05 | 0.87 (− 0.21, 1.94) | 0.053 |
| CD16blow/CD62Llow (%) | 0.14 ± 0.13 | 0.15 ± 0.09 | 0.17 ± 0.23 | 0.16 ± 0.09 | − 0.02 (− 0.18, 0.16) | 0.454 |
| CD16blow/CD62Lhigh (%) | 1.57 ± 0.69 | 2.16 ± 1.09 | 1.95 ± 1.41 | 2.49 ± 1.70 | − 0.05 (− 0.33, 0.24) | 0.363 |
Data expressed as mean ± SD or mean difference (95% CI). MFI median fluorescent intensity. Of the 20 COPD patients measured in phase 1, four were lost in the follow-up for the measurement of neutrophil activation markers